TMCnet News
Steroidstocks.com Lists Stocks on Steroids!!:(OTCBB:FBBN)-(OTCBB:CAEH)-(OTCBB:SBSW)(M2 PressWIRE Via Acquire Media NewsEdge) SteroidStocks.com Says:(OTCBB:FBBN) First Business Bank N.A., (OTCBB:CAEH) Caleco Pharma Corp and (OTCBB:SBSW) St. Bernard Software, Inc are on STEROIDS! SteroidStocks.com invites all investors to sign up at www.steroidstocks.com to subscribe to our FREE newsletter. To feature your publicly traded company in our alerts email us at [email protected] ------------------------------------------------------------------------------------------------------- About First Business Bank: Established in 2001, First Business Bank is locally owned and managed and committed to meeting the financial needs of small and medium-sized companies that make up San Diego's vibrant business community. Seasoned bankers, with an average of 21 years' experience, work one-on-one with clients to understand their unique needs and then utilize a full range of business and personal banking services to develop customized banking solutions that contribute to the growth and success of their business. First Business Bank remains one of the strongest, best-capitalized banks in Southern California, with a growing asset base and loan portfolio. For more information, please visit www.fbbank.com or call (858) 847-4780. News Today: SAN DIEGO, June 14, 2010--First Business Bank N.A. (OTC Bulletin Board: FBBN) has announced that the bank will change its name to Bank of Southern California effective Monday, June 28, 2010. Nathan Rogge, President and Chief Executive Officer of First Business Bank, said, "The process of selecting a new name has given us an opportunity to revisit our vision to be the best business bank in Southern California and to refine our branding and positioning for further growth. The name Bank of Southern California provides a strong identity for future expansion. "Our name will change," Rogge added, "but we remain committed to serving the banking needs of the local San Diego business and professional community as well as our clients' personal banking needs. The new name reinforces our dedication to delivering exceptional, personalized service to each of our clients throughout the vibrant Southern California region." Rogge said the name change resolves trademark issues with a bank in the Midwest that also carries the name First Business Bank. Rogge noted that the company's website address will be changed from www.fbbank.com to www.banksocal.com on June 28. The trading symbol for the company's common stock will remain FBBN. He added that there will be no changes in the bank's ownership, management or operations as a result of the name change. First Business Bank, which operates offices in Del Mar, Carlsbad and Ramona, had $124.5 million in assets as of March 31, 2010. ------------------------------------------------------------------------------------------------------ About Caleco Pharma Corp: http://www.calecopharmacorp.com/ Caleco Pharma is focused on the research, development and sales of its pipeline of over-the-counter and prescription medications including its proprietary antiviral and "Liver Health" OTC formulations. Caleco Pharma is developing Dermatological Products based on the active ingredients found in its proprietary formulation. To date, Caleco Pharma's intellectual property covering the Liver Health formulations and derivatives consists of patent applications in the United States, Europe and Canada and four European Drug Master File applications. Caleco Pharma's shares are traded in the United States on the OTC Bulletin Board (OTCBB: CAEH) and in Germany on the Frankfurt Stock Exchange (FRANKFURT: T3R)(WKN: A0N9Y0). News Today: LONG VALLEY, NEW JERSEY, Jun 14, 2010--(OTCBB: CAEH)(FRANKFURT: T3R)(WKN: A0N9Y0) (www.calecopharmacorp.com) Caleco Pharma Corp. (the "Company" or "Caleco"), is a diversified healthcare company with biopharmaceutical and consumer health products development programs. The company identifies and develops products derived from natural sources including plant extracts, functional oils and probiotics, and today announces that Mr. Luc Vanhal has joined the company in the role of Chief Financial Officer. Mr. Vanhal's stellar career brings experience as CFO and COO for NYSE and NASDAQ companies as well as Board of Director experience for many smaller emerging public companies. "I am excited about joining the team at Caleco Pharma at this key juncture in the Company's growth. Our broad product line, coupled with our dual pathways to market should help us ramp up the company's revenues very rapidly," said Mr. Vanhal. "There is a direct transfer of sourcing, manufacturing, marketing and sales expertise from my previous company to Caleco. We have built strong companies in the past and I am looking forward to repeating that experience here at Caleco." Mr. Vanhal was most recently the CFO and COO of Guthy-Renker, one of the world's largest direct response media companies with sales of more than $1.5 billion. The company develops, manufactures and markets celebrity endorsed products in areas such as skin care, cosmetics, hair care and fitness products. Mr. Vanhal's responsibilities included Finance, Accounting, IT, Human Resources, Customer Service, Inbound Telemarketing, Vendor management, Procurement, Manufacturing, Fulfillment, Distribution and Warehousing Prior to Guthy-Renker, he was Chief Operating and Financial Officer for Belkin Corporation, a technology leader in connectivity solutions, with overall worldwide responsibility for Finance, Accounting, IT, Procurement, Supply Chain, Human Resources, Strategic Planning, Distribution & Warehousing, and Legal departments. Belkin has offices in the US, Europe, Singapore, China and Australia. Mr. Vanhal was CFO and then President and COO of Vivendi Universal Games, the gaming unit of the French media and utilities conglomerate, Vivendi. Mr. Vanhal capped a ten year career at The Walt Disney Company as CFO of Disney's Consumer Products Division - Worldwide, a $3 Billion dollar division of Disney. Mr. Vanhal currently sits on the Board of Interplay Entertainment Corporation as member of the Audit Committee and the Compensation Committee. He was until recently on the Board of Directors of ViewSonic Corporation, where he was Chairman of the Audit Committee and a Member of the Governance and the Compensation committees. ----------------------------------------------------------------------------------------------------- About St. Bernard: St. Bernard Software develops and markets Internet security appliances and services that empower IT professionals to effectively, efficiently and intelligently manage their enterprise's Internet-based resources. Originally founded in 1995 as a market-leader in data security with its flagship product, Open File Manager(TM), the company is now recognized for delivering today's #1 Web filtering and security appliance, iPrism(R). With millions of end users worldwide in more than 5,000 enterprises, educational institutions, SMB, and government agencies, St. Bernard strives to deliver simple, high performance solutions that offer excellent value to our customers. Based in San Diego, California, St. Bernard (OTCBB: SBSW) markets its solutions through a network of value added resellers, distributors, system integrators, OEM partners and directly to end users. For more information about St. Bernard Software, visit www.stbernard.com. About Robert Hale and Associates: Robert Hale and Associates specializes in providing market research and consulting services for technology companies. With over 10 years experience in conducting market research, planning, strategy, and implementation support, our clients in the technology space include Qualcomm, Motorola, Samsung, Panasonic, Cisco, Microsoft, Mitchell International, and ViaSat. For more information, please visit www.roberthaleassociates.com. News Today: SAN DIEGO, CA, Jun 14, 2010--St. Bernard Software, Inc. (OTCBB: SBSW), a leader in Web security appliances, in conjunction with market research firm Robert Hale and Associates, today announced findings of the first US mid-enterprise market study quantifying four key areas that identify and define Total Cost of Acquisition (TCA) associated with Web security solutions. Among several key findings, the study confirmed that expenses surrounding TCA can be far greater than the initial purchase price, which significantly impacts an organization's return on investment (ROI) and total cost of ownership (TCO). Translating beyond the upfront initial purchase price, the study defines total cost of acquisition as all costs required to fully enable or deploy a Web filter solution or service. This latest study provides an objective measurement of IT time and investment in the following drivers of TCA for Web security: -- Total installation costs (includes servers, licenses, and other hardware purchases)-- Total set-up costs (includes costs associated with IT time, technical support, and professional services)-- Total purchase price of the Web filter-- Other relevant costs (includes technical support agreements and industry specific costs)"Our goal was to identify and examine all costs associated with acquiring and fully deploying a technology solution, beyond the initial purchase price," said Robert Hale, founder of Robert Hale and Associates. "So often buyers focus solely on the price tag, and aren't aware that the total acquisition cost typically includes additional, unexpected expenses that weren't accounted for when determining the ROI of their investment. For some companies these other costs can frequently be as high as 5x the purchase price of the Web filter." The study compared total acquisition costs between St. Bernard and Websense Web security solutions. Primary findings of the study included: -- St. Bernard's iPrism is almost half as costly to acquire and deploy than Websense. For a normalized (or typical) 750 seat enterprise, St. Bernard customers spent $24,774 in total Web filtering acquisition costs, compared to $43,138 for Websense-- 60% of Websense customers were required to purchase additional servers on top of the initial Web filter expense, compared to only 4% of St. Bernard customers-- Nearly 30% of Websense customers were required to purchase other additional hardware, compared to only 6% of St. Bernard customers-- 27% of Websense customers reported that the total amount of time for setup and installation of the Web filter solution was more than expected prior to purchase, versus only 9% of St. Bernard customers. Conversely, nearly 30% of St. Bernard customers reported that their setup and installation experience was easier than expected, compared to only 12% of Websense customers"In today's economy, it has become increasingly important for businesses to better manage their Total Cost of Ownership in order to maximize ROI. Better management of TCO begins with a clear understanding and examination of TCA," said Steve Yin, VP of global sales and marketing. "We understand that today's IT administrators have a responsibility to ensure that all technology investments are based on best overall efficiency and value, and we're pleased that our lower TCA will result in a higher ROI for our customers." Robert Hale and Associates conducted the study with a sample of 250 mid-enterprise IT professionals from commercial, financial, healthcare and manufacturing industries. The respondents were selected randomly from a database of companies sized 250 - 1,500 employees. The results are significant at the 95% level of confidence, and show important differences between St. Bernard and Websense in each of the measured areas. For more information about the study and the summary report, please visit www.stbernard.com/tcastudy. For more information regarding St. Bernard please visit www.stbernard.com or call 1-800-782-3762. ------------------------------------------------------------------------------------------------------- About SteroidStocks.com SteroidStocks.com is written and published by SteroidStocks.com employees. Readers are advised that this analysis report is issued solely for informational purposes. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SteroidStocks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. For additional information, please visit www.steroidstocks.com or e-mail [email protected]. ((Comments on this story may be sent to [email protected])) (c) 2010 M2 COMMUNICATIONS |